Is Acceleron Pharma Stock a Buy?
Last week, Acceleron Pharma (NASDAQ: XLRN) announced positive clinical trial results for its drug to treat a type of high blood pressure, causing its stock to skyrocket over 75%. After a jump that big, investors need to determine if the stock still has room to grow.
Image source: Getty Images.
Acceleron reported that its drug sotatercept successfully met the primary and secondary endpoints in a phase 2 clinical trial treating patients with pulmonary arterial hypertension (PAH). According to the American Lung Association, PAH occurs when small blood vessels in the lungs narrow in diameter, impeding blood flow through the lungs. It can lead to heart damage. Acceleron believes approximately 80,000 patients in the United States and Europe live with PAH. This program remains the most advanced of Acceleron's internal R&D efforts.
Source Fool.com
